Protocol Ledger

NCT07209761 · Phase III · RECRUITING

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Interventional Phase III clinical trial protocol NCT07209761 sponsored by Otsuka Pharmaceutical Development & Commercialization in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-16 Enrollment: 532 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07209761
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)532 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07209761
Protocol FieldVerified Registry Value
NCT IdentifierNCT07209761
Consolidated Lead SponsorOtsuka Pharmaceutical Development & Commercialization
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment532 participants (ESTIMATED)
Registered Start Date2025-10-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07209761
Hospital Research SiteLocationSite Profile
Huashan Hospital, Fudan UniversityShanghai, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI